On July 13, 2018, the U.S. Food and Drug Administration issued an alert of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. NDMA is classified as...
RECALL OF CERTAIN BLOOD PRESSURE AND HEART MEDICINES CONTAINING VALSARTAN AFTER DETECTION OF CARCINOGEN
